| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Study | Sourcelink | Webplotdigitizer | SAVE_lab | year | Assay Type | Cell-type | Sera details long | Number of sera | Comparator antigen | OmicronVariant | Titre drop | Uncertainty | numerical Titre drop | TitersHAg | TitersOmicron | Log2HAg | Log2Omi | Titre drop Alpha | TitersAlpha | Titre drop Beta | TitersBeta | Titre drop Gamma | TitersGamma | Titre drop Delta | TitersDelta | Sera_details_no_time | time | Standardised_sera_names | standardise_encounters | vacc_type_het | vacc_type | vaccine_manufacturer | standardised_assay | standardised_pseudo | standardised_cell | shared_data | internal_slides | manuscript_data | |
2 | Arien | https://www.medrxiv.org/content/10.1101/2021.12.23.21268316v1.full.pdf | n | 2021.12.24 | Live-virus | Vero | Infection + 3*Pfizer | 10 | WT | BA.1 | 20.4x | 20.4 | 4822 | 236 | 1159 | Infection + 3*Pfizer | Inf + 3*Pfizer | inf+vacc | inf+vacc | inf+vacc | inf+vacc | Live-virus | Live-virus | Vero | y | y | y | |||||||||||||
3 | Arien | https://www.medrxiv.org/content/10.1101/2021.12.23.21268316v1.full.pdf | n | 2021.12.24 | Live-virus | Vero | 2*Pfizer (28 days post 2nd dose) | 10 | WT | BA.1 | 13.1x | 13.1 | 2157 | 165 | 477 | 2*Pfizer | 28d post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Live-virus | Live-virus | Vero | y | y | y | ||||||||||||
4 | Arien | https://www.medrxiv.org/content/10.1101/2021.12.23.21268316v1.full.pdf | n | 2021.12.24 | Live-virus | Vero | D614G Hospitalized | 10 | WT | BA.1 | >>21.7x | >> | 21.7 | 1086 | 50 | 151 | WT hospitalized | WT acute | WT conv | WT conv | WT conv | WT conv | Live-virus | Live-virus | Vero | y | y | y | ||||||||||||
5 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 1*Janssen + boost | 8 | WT | BA.1 | >13x | > | 13x | 1201 | 1*Janssen + boost | <3m post boost | J&J + mRNA | 3 | heterologous | heterologous | heterologous | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||||
6 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 1*Janssen (less than 3 months) | 20 | WT | BA.1 | >1.4x | > | 1.4x | 42 | 1*Janssen | <3m post 2nd dose | J&J | 2 | j&j | j&j | j&j | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||||
7 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 1*Janssen. (6-12 months) | 6 | WT | BA.1 | >>1.6x | >> | 1.6x | 33 | 1*Janssen | 6-12m post dose | J&J | 2 | j&j | j&j | j&j | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||||
8 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Moderna (less than 3 months) | 24 | WT | BA.1 | >>43x | >> | 43x | 1362 | 3.16744186 | 430 | 2*Moderna | <3m post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||
9 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Moderna (6-12 months) | 23 | WT | BA.1 | >>8x | >> | 8x | 192 | 5.485714286 | 35 | 2*Moderna | 6-12m post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||
10 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Pfizer (less than 3 months) | 21 | WT | BA.1 | >>122x | >> | 122x | 2402 | 21.44642857 | 112 | 2*Pfizer | <3m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||
11 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Pfizer (6-12 months) | 33 | WT | BA.1 | >>3x | >> | 3x | 78 | 2.785714286 | 28 | 2*Pfizer | 6-12m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||
12 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Moderna + boost | 33 | WT | BA.1 | 6x | 6x | 2862 | 1.949591281 | 1468 | 2*Moderna + boost | <3m post 3rd dose | 2*Moderna + Moderna | 3 | mRNA | mRNA | moderna | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | |||||||||||
13 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Pfizer + boost | 30 | WT | BA.1 | 4x | 4x | 2219 | 1.98125 | 1120 | 2*Pfizer + boost | <3m post 3rd dose | 2*Pfizer + Pfizer | 3 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | |||||||||||
14 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Moderna + infection (6-12 months) | 8 | WT | BA.1 | >9x | > | 9x | 904 | 2.860759494 | 316 | 2*Moderna + infection | 6-12m post 2nd dose | 2*Moderna + Inf | vacc+inf | vacc+inf | vacc+inf | vacc+inf | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||
15 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Pfizer + infection (6-12 months) | 27 | WT | BA.1 | >12x | > | 12x | 947 | 3.978991597 | 238 | 2*Pfizer + infection | 6-12m post 2nd dose | 2*Pfizer + Inf | vacc+inf | vacc+inf | vacc+inf | vacc+inf | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||
16 | Balazs | https://balazslab.partners.org/pdfs/051%20-%20MedRxiv-Garcia-Belran,2021.pdf | y (Delta titers) | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 1*Janssen + infection (6-12 months) | 6 | WT | BA.1 | >>17x | >> | 17x | 603 | 1*Janssen + infection | 6-12m post dose | J&J + Inf | vacc+inf | vacc+inf | vacc+inf | vacc+inf | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||||
17 | Barouch | https://doi.org/10.1101/2022.01.02.22268634 | n | y | 2022.01.03 | Lenti-CMV Pseudotype | HEK293T-hACE2 | J&J (1m post dose) | 20 | WA1 | BA.1 | >>13.6 | >> | 272 | 20 | 20 | 39 | J&J | 1m post dose | J&J | 2 | j&j | j&j | j&j | Pseudovirus | Lenti-CMV | 293T-ACE2 | y | y | y | ||||||||||
18 | Barouch | https://doi.org/10.1101/2022.01.02.22268634 | n | y | 2022.01.03 | Lenti-CMV Pseudotype | HEK293T-hACE2 | J&J (8m post dose) | 20 | WA1 | BA.1 | >>9.2 | >> | 184 | 20 | 78 | 60 | J&J | 8m post dose | J&J | 2 | j&j | j&j | j&j | Pseudovirus | Lenti-CMV | 293T-ACE2 | y | y | y | ||||||||||
19 | Barouch | https://doi.org/10.1101/2022.01.02.22268634 | n | y | 2022.01.03 | Lenti-CMV Pseudotype | HEK293T-hACE2 | 2*Pfizer (1m post 2nd dose) | 31 | WA1 | BA.1 | >19.6 | > | 512 | 26 | 115 | 161 | 2*Pfizer | 1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lenti-CMV | 293T-ACE2 | y | y | y | ||||||||||
20 | Barouch | https://doi.org/10.1101/2022.01.02.22268634 | n | y | 2022.01.03 | Lenti-CMV Pseudotype | HEK293T-hACE2 | 2*Pfizer (8m post 2nd dose) | 31 | WA1 | BA.1 | >>8 | >> | 160 | 20 | 54 | 69 | 2*Pfizer | 8m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lenti-CMV | 293T-ACE2 | y | y | y | ||||||||||
21 | Chen | https://doi.org/10.1101/2021.12.17.21267961 | n | n | 2021.12.20 | Lentiviral pseudotype | HEK293T-ACE2 | 2*CoronaVac + CoronaVac (1m post 3rd dose) | 292 | WT | BA.1 | >20.1x | > | 20.1x | 294.85 | 14.66 | 2*CoronaVac + CoronaVac | 1m post 3rd dose | 2*CoronaVac + CoronaVac | 3 | other | other | other | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | |||||||||||
22 | Cicin-Sain | https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1.full.pdf | n | 2021.12.21 | VSV Pseudotype | VeroE6 | AZ+Moderna | 11 | B.1 | BA.1 | >17.5x | > | 17.5 | 1323 | 75.6 | 368.9 | 923.8 | AZ+Moderna | AZ + Moderna | 2 | heterologous | az+mRNA | heterologous | Pseudovirus | VSV | VeroE6 | y | y | y | |||||||||||
23 | Cicin-Sain | https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1.full.pdf | n | 2021.12.21 | VSV Pseudotype | VeroE6 | AZ+Pfizer | 15 | B.1 | BA.1 | 14.7x | 14.7 | 902.8 | 61.5 | 173.9 | 173.9 | AZ+Pfizer | AZ + Pfizer | 2 | heterologous | az+mRNA | heterologous | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
24 | Cicin-Sain | https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1.full.pdf | n | 2021.12.21 | VSV Pseudotype | VeroE6 | 2*AZ | 14 | B.1 | BA.1 | >12.8x | > | 12.8 | 186.4 | 14.6 | 46.4 | 95.3 | 2*AZ | 2*AZ | 2 | mRNA | mRNA | az | Pseudovirus | VSV | VeroE6 | y | y | y | |||||||||||
25 | Cicin-Sain | https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1.full.pdf | n | 2021.12.21 | VSV Pseudotype | VeroE6 | 2*Moderna | 16 | B.1 | BA.1 | 15.8x | 15.8 | 526 | 33.2 | 119.6 | 481.5 | 2*Moderna | 2*Moderna | 2 | mRNA | mRNA | mRNA | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
26 | Cicin-Sain | https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1.full.pdf | n | 2021.12.21 | VSV Pseudotype | VeroE6 | 2*Pfizer | 15 | B.1 | BA.1 | >28.7x | > | 28.7 | 393 | 13.7 | 56.6 | 503.5 | 2*Pfizer | 28d post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||
27 | Cicin-Sain | https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1.full.pdf | n | 2021.12.21 | VSV Pseudotype | VeroE6 | 2*Pfizer | 15 | B.1 | BA.1 | >7.5x | > | 7.5 | 82.6 | 10.9 | 31.3 | 85.7 | 2*Pfizer | 173d post second dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||
28 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 1*AZ+1*Pfizer (6 months post 2nd dose) | 19 | Delta | BA.1 | >>10.0x | >> | 10.0x | 2.94 | 1*AZ+1*Pfizer | 6m post 2nd dose | AZ + Pfizer | 2 | heterologous | az+mRNA | heterologous | Live-virus | Live-virus | Caco-2 | y | y | y | ||||||||||||
29 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 1*AZ+1*Pfizer + Pfizer boost (0.5 months post 3rd dose) | 8 | Delta | BA.1 | >27.1x | > | 27.1x | 78.27 | 1*AZ+1*Pfizer + Pfizer boost | 0.5m post 3rd dose | AZ + 2*Pfizer | 3 | heterologous | az+mRNA | heterologous | Live-virus | Live-virus | Caco-2 | y | y | y | ||||||||||||
30 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 2*Moderna (6 months post 2nd dose) | 14 | Delta | BA.1 | >>20.0x | >> | 20.0x | 11.58 | 2*Moderna | 6m post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Live-virus | Live-virus | Caco-2 | y | y | y | ||||||||||||
31 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 2*Pfizer (6 months post 2nd dose) | 15 | Delta | BA.1 | >>11.4x | >> | 11.4x | 5.833 | 2*Pfizer | 6m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Live-virus | Live-virus | Caco-2 | y | y | y | ||||||||||||
32 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 2*Moderna + Pfizer boost (0.5 months post 3rd dose) | 9 | Delta | BA.1 | 22.7x | 22.7x | 198.55 | 2*Moderna + Pfizer boost | 0.5m post 3rd dose | 2*Moderna + Pfizer | 3 | mRNA | mRNA | moderna | Live-virus | Live-virus | Caco-2 | y | y | y | |||||||||||||
33 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 2*Pfizer + Pfizer boost (0.5 months post 3rd dose) | 12 | Delta | BA.1 | 37.0x | 37.0x | 134.17 | 2*Pfizer + Pfizer boost | 0.5m post 3rd dose | 2*Pfizer + Pfizer | 3 | mRNA | mRNA | pfizer | Live-virus | Live-virus | Caco-2 | y | y | y | |||||||||||||
34 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 2*Pfizer + Pfizer boost (3 months post 3rd dose) | 20 | Delta | BA.1 | >24.5x | > | 24.5x | 45.66 | 2*Pfizer + Pfizer boost | 3m post 3rd dose | 2*Pfizer + Pfizer | 3 | mRNA | mRNA | pfizer | Live-virus | Live-virus | Caco-2 | y | y | y | ||||||||||||
35 | Ciesek | https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v4 | y (titers) | n | 2021 | Live-virus | Caco2 | 2*Pfizer + SARS-CoV-2 infection | 20 | Delta | BA.1 | >32.8x | > | 32.8x | 134.17 | 2*Pfizer + SARS-CoV-2 infection | 2*Pfizer + Inf | vacc+inf | vacc+inf | vacc+inf | vacc+inf | Live-virus | Live-virus | Caco-2 | y | y | y | |||||||||||||
36 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6-TMPRSS2 | 2*AZ (<1 months post 2nd dose) | 12 | D614G | BA.1 | >>36x | >> | 36x | 304 | 8 | 2*AZ | <1m post 2nd dose | 2*AZ | 2 | az | az | az | Pseudovirus | VSV | VeroE6-TMPRSS2 | y | y | y | |||||||||||
37 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6-TMPRSS2 | J&J (1-19 weeks post dose) | 12 | D614G | BA.1 | >>8.2x | >> | 8.2x | 41 | 5 | J&J | 1-19w post dose | J&J | 2 | j&j | j&j | j&j | Pseudovirus | VSV | VeroE6-TMPRSS2 | y | y | y | |||||||||||
38 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6-TMPRSS2 | 2*Moderna vs. B.1(<1 months post 2nd dose) | 14 | D614G | BA.1 | 33x | 33x | 926 | 29 | 2*Moderna | <1m post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Pseudovirus | VSV | VeroE6-TMPRSS2 | y | y | y | ||||||||||||
39 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6-TMPRSS2 | 2*Pfizer (<1 months post 2nd dose) | 17 | D614G | BA.1 | >44x | > | 44x | 708 | 16 | 2*Pfizer | <1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | VSV | VeroE6-TMPRSS2 | y | y | y | |||||||||||
40 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6-TMPRSS2 | BBIBP-CorV (<1 months post 2nd dose) | 13 | D614G | BA.1 | >>15.4x | >> | 15.4x | 108 | 7 | BBIBP-CorV | <1m post 2nd dose | CoronaVac | 2 | other | other | other | Pseudovirus | VSV | VeroE6-TMPRSS2 | y | y | y | |||||||||||
41 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6-TMPRSS2 | Sputnik V (<1 months post 2nd dose) | 11 | D614G | BA.1 | >>11.5x | >> | 11.5x | 46 | 4 | Sputnik V | <1m post 2nd dose | SputnikV | 2 | other | other | other | Pseudovirus | VSV | VeroE6-TMPRSS2 | y | y | y | |||||||||||
42 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6-TMPRSS2 | WT cnovalescent vs. B.1 (<1 months post infection) | 12 | D614G | BA.1 | >13.6x | > | 13.6x | 68 | 5 | WT covalescent | <1m post inf | WT conv | WT conv | WT conv | WT conv | WT conv | Pseudovirus | VSV | VeroE6-TMPRSS2 | y | y | y | |||||||||||
43 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6 | WT convalescent + Pfizer HCW (<1 months post 2nd dose) | 22 | Wu-1 | BA.1 | 5x | 5x | 2371 | 536 | WT convalescent + Pfizer HCW | <1m post 2nd dose | WT conv + Pfizer | inf+vacc | inf+vacc | inf+vacc | inf+vacc | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
44 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6 | 2*Moderna vs. WT (<1 months post 2nd dose) | 20 | Wu-1 | BA.1 | 15x | 15x | 1695 | 196 | 2*Moderna | <1m post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
45 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6 | 2* Pfizer HCW (<1 months post 2nd dose) | 25 | Wu-1 | BA.1 | >12x | > | 12x | 750 | 65 | 2* Pfizer HCW | <1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | VSV | VeroE6 | y | y | y | |||||||||||
46 | Corti | https://doi.org/10.1101/2021.12.12.472269 | y | n | 2021 | VSV Pseudotype | VeroE6 | WT covalescent vs. WT (<1 months post infection) | 12 | Wu-1 | BA.1 | >57x | > | 57x | 3481 | 65 | WT covalescent | <1m post inf | WT conv | WT conv | WT conv | WT conv | WT conv | Pseudovirus | VSV | VeroE6 | y | y | y | |||||||||||
47 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | Alpha convalescent | 12 | B.1 | BA.1 | >>35 | 27.8 | 0.8 | 45.5 | 7.4 | 3.8 | 5.9 | Alpha convalescent | 8-42d post inf | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||
48 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | Beta convalescent | 8 | B.1 | BA.1 | >6.5 | 6 | 0.9 | 2.6 | 20.6 | 2.6 | 3.2 | Beta convalescent | 3-98d post inf | Beta conv | Beta conv | Beta conv | Beta conv | Beta conv | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||
49 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | Delta convalescent | 10 | B.1 | BA.1 | 8.2 | 25.1 | 3.1 | 18.4 | 13.2 | 15 | 72.8 | Delta convalescent | 9-118d post inf | Delta conv | Delta conv | Delta conv | Delta conv | Delta conv | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||
50 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | Gamma convalescent | 10 | B.1 | BA.1 | 10x | 20.5 | 2.1 | 13.9 | 18.3 | 55.6 | 3.2 | Gamma convalescent | 7-137d post inf | Gamma conv | Gamma conv | Gamma conv | Gamma conv | Gamma conv | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||
51 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | Inf + 2*mRNA | 6 | B.1 | BA.1 | 18.2 | 1190.4 | 65.2 | 683.2 | 260.4 | 360.4 | 494.1 | Inf + 2*mRNA | Inf + 2*mRNA | inf+vacc | inf+vacc | inf+vacc | inf+vacc | Live-virus | Live-virus | VeroE6 | y | y | y | |||||||||||
52 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | 2*mRNA | 16 | B.1 | BA.1 | 85.7 | 338 | 3.9 | 121.7 | 49.3 | 62.8 | 95.6 | 2*mRNA | 1m post 2nd dose | 2*mRNA | 2 | mRNA | mRNA | mRNA | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||
53 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | WT conv | 34 | B.1 | BA.1 | >>45.6 | 37.3 | 0.8 | 16.7 | 14 | 10.3 | 12 | WT conv | 25-37d post inf | WT conv | WT conv | WT conv | WT conv | WT conv | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||
54 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | 1/2*mRNA + Omicron | 4 | Delta | BA.1 | 0.7 | 627.9 | 913.5 | 1/2*mRNA + Omicron | 16d post 2nd dose | 1/2*mRNA + Omicron | vacc+inf | vacc+inf | vacc+inf | vacc+inf | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||||||
55 | Eckerle | https://doi.org/10.1101/2021.12.28.21268491 | n | 2021.12.31 | Live-virus | VeroE6 | 2*mRNA + Delta | 4 | Delta | BA.1 | 12.5 | 1636 | 130.9 | 2*mRNA + Delta | 37-60d post 2nd dose | 2*mRNA + Delta | vacc+inf | vacc+inf | vacc+inf | vacc+inf | Live-virus | Live-virus | VeroE6 | y | y | y | ||||||||||||||
56 | Gao | https://doi.org/10.1101/2021.12.16.472391 | n | n | 2021.12.20 | VSV Pseudovirus | Vero | 2*CoronaVac + CoronaVac | 16 | WT | BA.1 | >5.1x | > | 5.1x | 284 | 56 | 1.3x | 226 | 2.2x | 131 | 1.7x | 171 | 2*CoronaVac + CoronaVac | 2*CoronaVac + CoronaVac | 3 | other | other | other | Pseudovirus | VSV | Vero | y | y | y | ||||||
57 | Gao | https://doi.org/10.1101/2021.12.16.472391 | n | n | 2021.12.20 | VSV Pseudovirus | Vero | WT convalescent | 16 | WT | BA.1 | >>11.1x | >> | 11.1x | 193 | 11.1 | 2.0x | 97 | 6.4x | 30 | 1.3x | 147 | WT convalescent | WT conv | WT conv | WT conv | WT conv | WT conv | Pseudovirus | VSV | Vero | y | y | y | ||||||
58 | Gruell | https://doi.org/10.1101/2021.12.14.21267769 | n | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | WT convalescent + Pfizer boost (2 months post boost) | 30 | Wu-1 | BA.1 | 5.162685604 | 5.162685604 | 7997 | 1549 | WT convalescent + Pfizer boost | 2m post 3rd dose | Inf + Pfizer | inf+vacc | inf+vacc | inf+vacc | inf+vacc | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||||
59 | Gruell | https://doi.org/10.1101/2021.12.14.21267769 | n | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Pfizer (1 month post 2nd dose) | 30 | Wu-1 | BA.1 | >>68.25x | >> | 68.25x | 546 | 8 | 2*Pfizer | 1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | |||||||||||
60 | Gruell | https://doi.org/10.1101/2021.12.14.21267769 | n | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Pfizer (5 month post 2nd dose) | 30 | Wu-1 | BA.1 | >15.4x | > | 15.4x | 139 | 9 | 2*Pfizer | 5m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | |||||||||||
61 | Gruell | https://doi.org/10.1101/2021.12.14.21267769 | n | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | 2*Pfizer + boost (1 month post boost) | 30 | Wu-1 | BA.1 | 5.218227425 | 5.218227425 | 6241 | 1196 | 2*Pfizer + Pfizer boost | 1m post 3rd dose | 2*Pfizer + Pfizer | 3 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||||
62 | Gruell | https://doi.org/10.1101/2021.12.14.21267769 | n | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | WT convalescent (1.5 months after recovery) | 30 | Wu-1 | BA.1 | 82.3x | 82.3x | 494 | 6 | WT convalescent | 1.5m post inf | WT conv | WT conv | WT conv | WT conv | WT conv | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | ||||||||||||
63 | Gruell | https://doi.org/10.1101/2021.12.14.21267769 | n | n | 2021 | Lentiviral Pseudotype | HEK293T-ACE2 | WT convalescent (12 month after recovery) | 30 | Wu-1 | BA.1 | >11.625x | > | 11.625x | 93 | 8 | WT convalescent | 12m post inf | WT conv | WT conv | WT conv | WT conv | WT conv | Pseudovirus | Lentiviral | 293T-ACE2 | y | y | y | |||||||||||
64 | Gupta | https://www.citiid.cam.ac.uk/wp-content/uploads/2021/12/FIGURES-OMICRON-PAPER.pdf | y | n | 2021 | Lentiviral Pseudotype | Vero E6 Ace2/TMPRSS2 | 2*AZ (1m post 2nd dose) | 20 | Delta | BA.1 | >>11.1x | >> | 11.1x | 222 | 20 | 2*AZ | 1m post 2nd dose | 2*AZ | 2 | az | az | az | Pseudovirus | Lentiviral | VeroE6-ACE2/TMPRSS2 | y | y | y | |||||||||||
65 | Gupta | https://www.citiid.cam.ac.uk/wp-content/uploads/2021/12/FIGURES-OMICRON-PAPER.pdf | y | n | 2021 | Lentiviral Pseudotype | Vero E6 Ace2/TMPRSS2 | 2*AZ (6m post 2nd dose) | 20 | Delta | BA.1 | >>6.7x | >> | 6.7x | 67 | 10 | 2*AZ | 6m post 2nd dose | 2*AZ | 2 | az | az | az | Pseudovirus | Lentiviral | VeroE6-ACE2/TMPRSS2 | y | y | y | |||||||||||
66 | Gupta | https://www.citiid.cam.ac.uk/wp-content/uploads/2021/12/FIGURES-OMICRON-PAPER.pdf | y | n | 2021 | Lentiviral Pseudotype | Vero E6 Ace2/TMPRSS2 | 2*AZ + Pfizer (1m post 3rd dose) | 20 | Delta | BA.1 | 3.3x | 3.3x | 4061 | 1221 | 2*AZ + Pfizer | 1m post 3rd dose | 2*AZ + Pfizer | 3 | heterologous | az+mRNA | heterologous | Pseudovirus | Lentiviral | VeroE6-ACE2/TMPRSS2 | y | y | y | ||||||||||||
67 | Gupta | https://www.citiid.cam.ac.uk/wp-content/uploads/2021/12/FIGURES-OMICRON-PAPER.pdf | y | n | 2021 | Lentiviral Pseudotype | Vero E6 Ace2/TMPRSS2 | 2*Pfizer (1m post 2nd dose) | 20 | Delta | BA.1 | >2.8x | > | 2.8x | 1110 | 390 | 2*Pfizer | 1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | VeroE6-ACE2/TMPRSS2 | y | y | y | |||||||||||
68 | Gupta | https://www.citiid.cam.ac.uk/wp-content/uploads/2021/12/FIGURES-OMICRON-PAPER.pdf | y | n | 2021 | Lentiviral Pseudotype | Vero E6 Ace2/TMPRSS2 | 2*Pfizer (6m post 2nd dose) | 20 | Delta | BA.1 | >2.6x | > | 2.6x | 351 | 137 | 2*Pfizer | 6m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | VeroE6-ACE2/TMPRSS2 | y | y | y | |||||||||||
69 | Gupta | https://www.citiid.cam.ac.uk/wp-content/uploads/2021/12/FIGURES-OMICRON-PAPER.pdf | y | n | 2021 | Lentiviral Pseudotype | Vero E6 Ace2/TMPRSS2 | 2*Pfizer + Pfizer (1m post 3rd dose) | 20 | Delta | BA.1 | 2.3x | 2.3x | 8111 | 3511 | 2*Pfizer + Pfizer | 1m post 3rd dose | 2*Pfizer + Pfizer | 3 | mRNA | mRNA | pfizer | Pseudovirus | Lentiviral | VeroE6-ACE2/TMPRSS2 | y | y | y | ||||||||||||
70 | HKU | http://www.med.hku.hk/en/news/press/20211212-omicron-avoids-killing-by-blood-serum | n | n | 2021 | Live virus | Unknown | 2*Pfizer (1 month post 2nd dose) | 10 | WT | BA.1+R346K | >32 | > | 32 | 2*Pfizer | 1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||||
71 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | VSV Pseudovirus | Vero-E6 | 2*AZ (some vaccinated + infected) | 5 | D614G | BA.1+R346K | >>1.57x | >> | 1.57x | 157 | 100 | 2*AZ (some vaccinated + infected) | 2*AZ | 2 | az | az | az | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
72 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | VSV Pseudovirus | Vero-E6 | J&J (some vaccinated + infected) | 9 | D614G | BA.1+R346K | >>2.5x | >> | 2.5x | 388 | 153 | J&J (some vaccinated + infected) | J&J | 2 | j&j | j&j | j&j | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
73 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | VSV Pseudovirus | Vero-E6 | 2*Moderna (>2w post 2nd dose) | 12 | D614G | BA.1+R346K | 9.3x | 9.3x | 7921 | 848 | 2*Moderna (>2w post 2nd dose) | >2w post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
74 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | Live-virus | Vero-TMPRSS2 | 2*mRNA (Moderna or Pfizer) (>2w post 2nd dose) | 17 | D614G | BA.1+R346K | >>6x | >> | 6x | 905 | 152 | 2*mRNA (Moderna or Pfizer) | >2w post 2nd dose | 2*mRNA | 2 | mRNA | mRNA | mRNA | Live-virus | Live-virus | Vero-TMPRSS2 | y | y | y | |||||||||||
75 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | VSV Pseudovirus | Vero-E6 | 2*Pfizer (some vaccinated + infected) (>2w post 2nd dose) | 13 | D614G | BA.1+R346K | >21x | > | 21x | 4669 | 222 | 2*Pfizer (some vaccinated + infected) | >2w post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Pseudovirus | VSV | VeroE6 | y | y | y | |||||||||||
76 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | VSV Pseudovirus | Vero-E6 | 2*mRNA + homologous boost PV (n= 13 Pfizer, n= 2 Moderna) (>2w post 3rd dose) | 15 | D614G | BA.1+R346K | 6.5x | 6.5x | 4673 | 715 | 2*mRNA + homologous boost (n= 13 Pfizer, n= 2 Moderna) | >2w post 3rd dose | 2*mRNA + mRNA | 3 | mRNA | mRNA | mRNA | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
77 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | Live-virus | Vero-TMPRSS2 | 2*mRNA + homologous boost LV (n= 13 Pfizer, n= 2 Moderna) (>2w post 3rd dose) | 12 | D614G | BA.1+R346K | >>4.1x | >> | 4.1x | 584 | 143 | 2*mRNA + homologous boost (n= 13 Pfizer, n= 2 Moderna) | >2w post 3rd dose | 2*mRNA + mRNA | 3 | mRNA | mRNA | mRNA | Live-virus | Live-virus | Vero-TMPRSS2 | y | y | y | |||||||||||
78 | Ho | https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.article-info | n | y | 2021 | VSV Pseudovirus | Vero-E6 | WT convalescent | 10 | D614G | BA.1+R346K | >>32.2x | >> | 32.2x | 4344 | 135 | WT convalescent | WT conv | WT conv | WT conv | WT conv | WT conv | Pseudovirus | VSV | VeroE6 | y | y | y | ||||||||||||
79 | Israel MoH | https://twitter.com/JScholar/status/1470110894856286216/photo/1 | n | n | 2021 | Live-virus | Unknown | 2*vacc | Wu-1? | BA.1 | >>14.9x | >> | 14.9x | 16.56 | 1.11 | 1.27 | 8 | 2*vacc | 2*Vacc | 2 | mRNA | mRNA | mRNA | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
80 | Israel MoH | https://twitter.com/JScholar/status/1470110894856286216/photo/1 | n | n | 2021 | Live-virus | Unknown | 3*vacc | Wu-1? | BA.1 | 8.3x | 8.3x | 891.4 | 107.6 | 152.2 | 430.5 | 3*vacc | 2*Vacc + Vacc | 3 | mRNA | mRNA | mRNA | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
81 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Alpha (B.1.1.7) convalescent | 10 | Alpha | BA.1 | >>35.3 | >> | 35.3 | 282.6 | 8 | Alpha (B.1.1.7) convalescent | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
82 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 2*AZ | 10 | Alpha | BA.1 | >>23.8 | >> | 23.8 | 190.2 | 8 | 2*AZ | 1m post 2nd dose | 2*AZ | 2 | az | az | az | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
83 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Beta (B.1.351) convalescent | 8 | Alpha | BA.1 | >>18.9 | >> | 18.9 | 151 | 8 | Beta (B.1.351) convalescent | Beta conv | Beta conv | Beta conv | Beta conv | Beta conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
84 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Delta (B.1.617.2) convalescent | 7 | Alpha | BA.1 | >>24.6 | >> | 24.6 | 196.6 | 8 | Delta (B.1.617.2) convalescent | Delta conv | Delta conv | Delta conv | Delta conv | Delta conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
85 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 1*AZ+1*Pfizer | 20 | Alpha | BA.1 | >18.3 | > | 18.3 | 786.4 | 43.1 | 1*AZ+1*Pfizer | 1m post 2nd dose | AZ + Pfizer | 2 | heterologous | az+mRNA | heterologous | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
86 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 2*Moderna | 10 | Alpha | BA.1 | >>47.6 | >> | 47.6 | 380.4 | 8 | 2*Moderna | 4-6m post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
87 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 2*Pfizer | 20 | Alpha | BA.1 | >30 | > | 30 | 624.1 | 20.8 | 2*Pfizer | 1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
88 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Alpha (B.1.1.7) convalescent | 10 | Beta | BA.1 | >>20.8 | >> | 20.8 | 166.7 | 8 | Alpha (B.1.1.7) convalescent | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
89 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 2*AZ | 10 | Beta | BA.1 | >>13.6 | >> | 13.6 | 108.5 | 8 | 2*AZ | 1m post 2nd dose | 2*AZ | 2 | az | az | az | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
90 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Beta (B.1.351) convalescent | 8 | Beta | BA.1 | >>64 | >> | 64 | 512 | 8 | Beta (B.1.351) convalescent | Beta conv | Beta conv | Beta conv | Beta conv | Beta conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
91 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Delta (B.1.617.2) convalescent | 7 | Beta | BA.1 | >>23 | >> | 23 | 184 | 8 | Delta (B.1.617.2) convalescent | Delta conv | Delta conv | Delta conv | Delta conv | Delta conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
92 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 1*AZ+1*Pfizer | 20 | Beta | BA.1 | >10.4 | > | 10.4 | 448.7 | 43.1 | 1*AZ+1*Pfizer | 1m post 2nd dose | AZ + Pfizer | 2 | heterologous | az+mRNA | heterologous | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
93 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 2*Moderna | 10 | Beta | BA.1 | >>24.6 | >> | 24.6 | 196.6 | 8 | 2*Moderna | 4-6m post 2nd dose | 2*Moderna | 2 | mRNA | mRNA | moderna | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
94 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 2*Pfizer | 20 | Beta | BA.1 | >15 | > | 15 | 312.1 | 20.8 | 2*Pfizer | 1m post 2nd dose | 2*Pfizer | 2 | mRNA | mRNA | pfizer | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
95 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Alpha (B.1.1.7) convalescent | 10 | Delta | BA.1 | >>7.7 | >> | 7.7 | 61.9 | 8 | Alpha (B.1.1.7) convalescent | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Alpha conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
96 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 2*AZ | 10 | Delta | BA.1 | >>15.5 | >> | 15.5 | 123.8 | 8 | 2*AZ | 1m post 2nd dose | 2*AZ | 2 | az | az | az | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
97 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Beta (B.1.351) convalescent | 8 | Delta | BA.1 | >>7.2 | >> | 7.2 | 58 | 8 | Beta (B.1.351) convalescent | Beta conv | Beta conv | Beta conv | Beta conv | Beta conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
98 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Delta (B.1.617.2) convalescent | 7 | Delta | BA.1 | >>47.6 | >> | 47.6 | 380.4 | 8 | Delta (B.1.617.2) convalescent | Delta conv | Delta conv | Delta conv | Delta conv | Delta conv | Live-virus | Live-virus | Unknown | y | y | y | ||||||||||||
99 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | 1*AZ+1*Pfizer | 20 | Delta | BA.1 | >11.1 | > | 11.1 | 479.3 | 43.1 | 1*AZ+1*Pfizer | 1m post 2nd dose | AZ + Pfizer | 2 | heterologous | az+mRNA | heterologous | Live-virus | Live-virus | Unknown | y | y | y | |||||||||||
100 | Kimpel | https://doi.org/10.1101/2021.12.08.21267491 | y | n | 2021 | Live-virus | Unknown | Infection then vaccine | 5 | Delta | BA.1 | 3.6 | 3.6 | 868.2 | 239.6 | Infection then vaccine | Inf + Vacc | inf+vacc | inf+vacc | inf+vacc | inf+vacc | Live-virus | Live-virus | Unknown | y | y | y |